Cover Image
Market Research Report
Product code 
232813

Duchenne Muscular Dystrophy (Genitourinary Disorders) - Drugs In Development, 2021

Published: | Global Markets Direct | 489 Pages | Delivery time: 1-2 business days

Price

Back to Top
Duchenne Muscular Dystrophy (Genitourinary Disorders) - Drugs In Development, 2021
Published: July 30, 2021
Global Markets Direct
Content info: 489 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2021, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 5, 14, 10, 3, 68, 27 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 2, 1, 12 and 2 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC12875IDB

Table of Contents

Table of Contents

  • Introduction
  • Duchenne Muscular Dystrophy - Overview
  • Duchenne Muscular Dystrophy - Therapeutics Development
  • Duchenne Muscular Dystrophy - Therapeutics Assessment
  • Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
  • Duchenne Muscular Dystrophy - Drug Profiles
  • Duchenne Muscular Dystrophy - Dormant Projects
  • Duchenne Muscular Dystrophy - Discontinued Products
  • Duchenne Muscular Dystrophy - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Duchenne Muscular Dystrophy, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Duchenne Muscular Dystrophy - Pipeline by 4D Molecular Therapeutics Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by AAVogen Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Alpha Anomeric, 2021
  • Duchenne Muscular Dystrophy - Pipeline by American CryoStem Corp, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Anagenesis Biotechnologies SAS, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Antisense Therapeutics Ltd, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Astellas Gene Therapies, 2021
  • Duchenne Muscular Dystrophy - Pipeline by AUM LifeTech Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Autotac Bio Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Avidity Biosciences Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Axolo Pharma Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Bayer AG, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Biogen Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by BioIncept LLC, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Bioleaders Corp, 2021
  • Duchenne Muscular Dystrophy - Pipeline by BioMarin Pharmaceutical Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Biophytis SA, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Code Biotherapeutics Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Consortium.AI, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Constant Therapeutics LLC, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Tivorsan Pharmaceuticals Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Tolerion Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Triplex Therapeutics Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by UGISense AG, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Ultragenyx Pharmaceutical Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Vertex Pharmaceuticals Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Vita Therapeutics Inc, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Wave Life Sciences Ltd, 2021
  • Duchenne Muscular Dystrophy - Pipeline by Zata Pharmaceuticals Inc, 2021
  • Duchenne Muscular Dystrophy - Dormant Projects, 2021
  • Duchenne Muscular Dystrophy - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Duchenne Muscular Dystrophy, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021